Abstract:The low fermentable oligosaccharide, disaccharide, monosaccharide and polyol (FODMAP) diet is recommended as a first line therapeutic management strategy for irritable bowel syndrome (IBS) (1) . The low FODMAP diet is supported by meta-analytical evidence (2) , and demonstrates acceptability and effectiveness for improving symptoms and quality of life (QoL) in 50-75% of individuals with IBS. However, a subset of individuals (25-50%) do not respond to the diet (3) . The identification of individual-level predictors of treatment response across all three phases of the low FODMAP diet is currently lacking. The study aims were to assess psychological predictors of symptom and QoL response to the low FODMAP diet in patients with IBS. Adults with IBS underwent a three-phase low FODMAP diet, guided by individualised dietetic education. Predictor variables included levels of depressive, anxiety, and extraintestinal somatic symptoms, stress, treatment beliefs and expectations, behavioural avoidance, and illness perceptions. Symptom severity and QoL were the main outcomes. Questionnaires assessing psychological predictors, symptoms and QoL were administered at five points: pre-dietitian (week 0), post-dietitian, end of elimination (week 5), end of reintroduction (week 13), and end of personalisation (week 25) phases. Latent class growth analysis was used to identify classes of response trajectories for symptoms. Linear mixed models were used to test the effect of baseline psychological scores on symptoms and QoL over time. Cross lagged panel models determined the directional predictive relationship between psychological predictors and symptom severity. 112 participants (89% F) median age 30 ± 17 years were included. There were three classes of symptom response trajectories, including 'non-improvers' (21.3% of participants) with high initial symptom severity and minimal improvement, 'improvers' (22.5% of participants) with low initial symptom severity and significant improvement, and an 'intermediate' group (56.2% of participants) with moderate initial symptom severity and significant improvement. Higher treatment beliefs predicted a stronger initial symptom response (effect on linear slope p = 0.036). Lower gut-specific anxiety, as well as higher levels of personal and treatment control at baseline predicted a stronger reduction in IBS symptom severity and improved QoL from week 0 to week 25. Participants with higher levels of baseline psychological symptoms and negative illness perceptions (i.e., lower emotional representations) predicted a stronger initial and later QoL response (effect on linear (p = 0.006) and quadratic (p = 0.049) slopes). Increased cyclical time beliefs predicted poorer initial and later QoL response (effect on linear (p = 0.015) and quadratic (p = 0.029) slopes). Individuals experiencing lower to mid-range symptom severity at baseline had greater improvement with the low FODMAP diet. Lower anxiety, positive illness views and higher treatment beliefs predict better QoL and symptom response. Personalised strategies are crucial for optimising low FODMAP diet effectiveness in IBS.

Acupuncture and radioactive pathways of hypodermically injected technetium-99m.

PWE-131 Fodmap Intake and the Risk of Irritable Bowel Syndrome in the Community: a Prospective Study

Long‐term personalized low FODMAP diet improves symptoms and maintains luminal Bifidobacteria abundance in irritable bowel syndrome

Implementation of an Erlang-Based Resource Holon for a Holonic Manufacturing Cell

Low-FODMAP Diet Improves Irritable Bowel Syndrome Symptoms: A Meta-Analysis

A Low-FODMAP Diet for Irritable Bowel Syndrome: Some Answers to the Doubts from a Long-Term Follow-Up

Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: a systematic review and meta-analysis

Low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol diet in patients with diarrhea‐predominant irritable bowel syndrome: A prospective, randomized trial

Effects of a low FODMAP diet on the symptom management of patients with irritable bowel syndrome: a systematic umbrella review with the meta-analysis of clinical trials

Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial

A service evaluation of FODMAP restriction, FODMAP reintroduction and long‐term follow‐up in the dietary management of irritable bowel syndrome

Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis

Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date

Efficacy and findings of a blinded randomized reintroduction phase for the low FODMAP diet in Irritable Bowel Syndrome

High-level secretion of biologically active aprotinin from the yeastPichia pastoris

Predicting symptom response and quality of life to the low FODMAP diet in irritable bowel syndrome: a 6-month longitudinal study

A diet low in fermentable oligo‐, di‐, monosaccharides and polyols improves abdominal and overall symptoms in persons with all subtypes of irritable bowel syndrome

Nutritional safety and status following a 12-week strict low FODMAP diet in patients with irritable bowel syndrome

D = 4 supergravity dynamically coupled to a massless superparticle in a superfield Lagrangian approach

Serum Uric Acid Predicts Progression of Subclinical Coronary Atherosclerosis in Individuals Without Renal Disease